HG 301
Alternative Names: HG-301Latest Information Update: 04 Oct 2023
At a glance
- Originator HuidaGene Therapeutics
- Class Eye disorder therapies; Gene therapies
- Mechanism of Action Gene transference; Rhodopsin replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Retinitis pigmentosa
Most Recent Events
- 04 Oct 2023 Huidagene has patent protection for engineered crispr-cas13f system
- 12 Sep 2023 Preclinical trials in Retinitis pigmentosa in China, prior to September 2023 (Parenteral) (Huidagene pipeline, September 2023)
- 12 Sep 2023 Pharmacodynamics data from a preclinical trial in Retinitis pigmentosa released by Huidagene